{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T20:26:27Z","timestamp":1793823987268,"version":"4.6.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2022,7,18]],"date-time":"2022-07-18T00:00:00Z","timestamp":1658102400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,7,18]],"date-time":"2022-07-18T00:00:00Z","timestamp":1658102400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1245\/s10434-022-12193-w","type":"journal-article","created":{"date-parts":[[2022,7,18]],"date-time":"2022-07-18T14:02:59Z","timestamp":1658152979000},"page":"6267-6273","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["How Often Do Sentinel Lymph Node Biopsy Results Affect Adjuvant Therapy Decisions Among Postmenopausal Women with Early-Stage HR+\/HER2\u2212 Breast Cancer in the Post-RxPONDER Era?"],"prefix":"10.1245","volume":"29","author":[{"given":"Melissa","family":"Pilewskie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varadan","family":"Sevilimedu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Idil","family":"Eroglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiana","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Morrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lior Z.","family":"Braunstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,18]]},"reference":[{"issue":"10","key":"12193_CR1","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1001\/jama.2017.11470","volume":"318","author":"AE Giuliano","year":"2017","unstructured":"Giuliano AE, Ballman KV, McCall L, et al. Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) randomized clinical trial. JAMA. 2017;318(10):918\u201326.","journal-title":"JAMA"},{"issue":"2","key":"12193_CR2","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.prro.2016.09.007","volume":"7","author":"C Correa","year":"2017","unstructured":"Correa C, Harris EE, Leonardi MC, et al. Accelerated partial breast irradiation: executive summary for the update of an ASTRO evidence-based consensus statement. Pract Radiat Oncol. 2017;7(2):73\u20139.","journal-title":"Pract Radiat Oncol"},{"issue":"25","key":"12193_CR3","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1056\/NEJMoa2108873","volume":"385","author":"K Kalinsky","year":"2021","unstructured":"Kalinsky K, Barlow WE, Gralow JR, et al. 21-Gene assay to inform chemotherapy benefit in node-positive breast cancer. N Engl J Med. 2021;385(25):2336\u201347.","journal-title":"N Engl J Med"},{"issue":"3","key":"12193_CR4","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1097\/SLA.0000000000002354","volume":"266","author":"M Morrow","year":"2017","unstructured":"Morrow M, Van Zee KJ, Patil S, et al. Axillary dissection and nodal irradiation can be avoided for most node-positive Z0011-eligible breast cancers: a prospective validation study of 793 patients. Ann Surg. 2017;266(3):457\u201362.","journal-title":"Ann Surg"},{"issue":"5","key":"12193_CR5","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.ejso.2016.01.020","volume":"42","author":"O Gentilini","year":"2016","unstructured":"Gentilini O, Botteri E, Dadda P, et al. Physical function of the upper limb after breast cancer surgery. Results from the SOUND (sentinel node versus observation after axillary ultra-sound) trial. Eur J Surg Oncol. 2016;42(5):685\u20139.","journal-title":"Eur J Surg Oncol"},{"key":"12193_CR6","doi-asserted-by":"crossref","unstructured":"Gerber B, Stachs A, Veselinovic K, et al. Abstract No. GS4-03. Patient-reported outcomes (PROs) for the intergroup sentinel mamma study (INSEMA, GBG75, ABCSG43): persistent impact of axillary surgery on arm and breast symptoms in early breast cancer. Presented at the 2021 San Antonio Breast Cancer Symposium, 7\u201310 December 2021, San Antonio, TX.","DOI":"10.1158\/1538-7445.SABCS21-GS4-03"},{"issue":"34","key":"12193_CR7","doi-asserted-by":"publisher","first-page":"3987","DOI":"10.1200\/JCO.20.02514","volume":"38","author":"SRD Johnston","year":"2020","unstructured":"Johnston SRD, Harbeck N, Hegg R, et al. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2\u2212, node-positive, high-risk, early breast cancer (monarchE). J Clin Oncol. 2020;38(34):3987\u201398.","journal-title":"J Clin Oncol"},{"issue":"9","key":"12193_CR8","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa1910549","volume":"382","author":"P Schmid","year":"2020","unstructured":"Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020;382(9):810\u201321.","journal-title":"N Engl J Med"},{"issue":"2","key":"12193_CR9","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1056\/NEJMoa1406281","volume":"372","author":"SM Tolaney","year":"2015","unstructured":"Tolaney SM, Barry WT, Dang CT, et al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med. 2015;372(2):134\u201341.","journal-title":"N Engl J Med"},{"key":"12193_CR10","doi-asserted-by":"crossref","unstructured":"Dodwell D, Taylor C, P M, et al. Abstract No. GS4-02: Regional lymph node irradiation in early stage breast cancer: an EBCTCG meta-analysis of 13,000 women in 14 trials. Presented at the 2018 San Antonio Breast Cancer Symposium, 4\u20138 December 2018, San Antonio, TX. Cancer Res. 2019;79(4_Supplement):GS4\u201302.","DOI":"10.1158\/1538-7445.SABCS18-GS4-02"},{"issue":"12","key":"12193_CR11","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1016\/S1470-2045(20)30472-1","volume":"21","author":"PM Poortmans","year":"2020","unstructured":"Poortmans PM, Weltens C, Fortpied C, et al. Internal mammary and medial supraclavicular lymph node chain irradiation in stage I-III breast cancer (EORTC 22922\/10925): 15-year results of a randomised, phase 3 trial. Lancet Oncol. 2020;21(12):1602\u201310.","journal-title":"Lancet Oncol"},{"issue":"4","key":"12193_CR12","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1056\/NEJMoa1415340","volume":"373","author":"TJ Whelan","year":"2015","unstructured":"Whelan TJ, Olivotto IA, Parulekar WR, et al. Regional nodal irradiation in early-stage breast cancer. N Engl J Med. 2015;373(4):307\u201316.","journal-title":"N Engl J Med"},{"issue":"4","key":"12193_CR13","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/j.ijrobp.2019.02.050","volume":"104","author":"LZ Braunstein","year":"2019","unstructured":"Braunstein LZ, Thor M, Flynn J, et al. Daily fractionation of external beam accelerated partial breast irradiation to 40 gy is well tolerated and locally effective. Int J Radiat Oncol Biol Phys. 2019;104(4):859\u201366.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"10099","key":"12193_CR14","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/S0140-6736(17)31145-5","volume":"390","author":"CE Coles","year":"2017","unstructured":"Coles CE, Griffin CL, Kirby AM, et al. Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet. 2017;390(10099):1048\u201360.","journal-title":"Lancet"},{"issue":"2","key":"12193_CR15","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.ijrobp.2016.05.008","volume":"96","author":"JS Vaidya","year":"2016","unstructured":"Vaidya JS, Bulsara M, Wenz F, et al. Reduced mortality with partial-breast irradiation for early breast cancer: a meta-analysis of randomized trials. Int J Radiat Oncol Biol Phys. 2016;96(2):259\u201365.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"12193_CR16","doi-asserted-by":"crossref","unstructured":"Hughes KS, Schnaper LA, Berry D, et al. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med. 2004;351(10):971\u201377.","DOI":"10.1056\/NEJMoa040587"},{"key":"12193_CR17","doi-asserted-by":"crossref","unstructured":"Kunkler IH, Williams LJ, Jack WJ, Cameron DA, Dixon JM. Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial. Lancet Oncol. 2015;16(3):266\u201373.","DOI":"10.1016\/S1470-2045(14)71221-5"},{"key":"12193_CR18","unstructured":"The PRECISION Trial (Profiling Early Breast Cancer for Radiotherapy Omission): a phase II study of breast-conserving surgery without adjuvant radiotherapy for favorable-risk breast cancer. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02653755. Accessed 6 June 2022."},{"key":"12193_CR19","unstructured":"The IDEA Study (Individualized Decisions for Endocrine Therapy Alone). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02400190. Accessed 6 June 2022."},{"key":"12193_CR20","unstructured":"EXamining PErsonalised Radiation Therapy for Low-risk Early Breast Cancer (EXPERT). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02889874. Accessed 6 June 2022."},{"key":"12193_CR21","unstructured":"De-escalation of breast radiation trial for hormone sensitive, HER2-negative, oncotype recurrence score less than or equal to 18 breast cancer (DEBRA). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04852887. Accessed 6 June 2022."},{"issue":"1","key":"12193_CR22","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1186\/s12885-017-3443-x","volume":"17","author":"LM van Roozendaal","year":"2017","unstructured":"van Roozendaal LM, Vane MLG, van Dalen T, et al. Clinically node negative breast cancer patients undergoing breast conserving therapy, sentinel lymph node procedure versus follow-up: a Dutch randomized controlled multicentre trial (BOOG 2013\u201308). BMC Cancer. 2017;17(1):459.","journal-title":"BMC Cancer"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-022-12193-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-022-12193-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-022-12193-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T19:58:50Z","timestamp":1662753530000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-022-12193-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,18]]},"references-count":22,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["12193"],"URL":"https:\/\/doi.org\/10.1245\/s10434-022-12193-w","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,18]]},"assertion":[{"value":"27 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The preparation of this study was supported in part by NIH\/NCI Cancer Center Support Grant No. P30CA008748 to Memorial Sloan Kettering Cancer Center. Dr. Monica Morrow has received honoraria from Roche and Exact Sciences. All other authors have no relevant conflicts of interest to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}